On Monday, the market bears continued to dominate, the activity of the main board heavyweight stocks was slightly stronger than that of theme stocks, the market activity decreased significantly, the pressure increased, and only a few leading stocks remained active, but there was no plate effect.
The surge in transportation and shipping is event-driven, and the sustainability remains to be seen, so it is advisable to stay on the sidelines. Growth stocks are now collectively under pressure and have not performed well, and it is expected that the activity is expected to gradually pick up after the short-term market consolidates the bottom area. At present, we will remain on the sidelines.
The market selling pressure has further increased, but the bears' strength has weakened, and the bulls are expected to be ** after 4 consecutive yin. It will be interesting to see if the market bulls can fight back strongly on Tuesday and continue to stay on the sidelines until the bottom is consolidated.
Sinocare's blood glucose monitoring system products have obtained FDA 510 certification.
Halma Technology: A total of 2.35 million shares were repurchased.
China Merchants Shekou: From January to November, the cumulative contracted sales amount increased by 8 year-on-year35%
Shuanghuan Transmission: On December 5, the first repurchase of shares 114180,000 shares.
Sinocare Biologics: The blood glucose monitoring system product has obtained the US FDA 510 certification.
Betta Pharmaceuticals: CFT8919 tablets obtained the clinical trial approval notice.
Oriental Yuhong: 148 has been repurchased730,000 shares, with a total turnover of about 3,274220,000 yuan.
Muyuan shares: 879.1 billion yuan.